Compare ACGLO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F
Current Price
| Metric | ACGLO | VERA |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Bermuda | United States |
| Employees | 5800 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | ACGLO | VERA |
|---|---|---|
| Price | $20.25 | $53.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $76.60 |
| AVG Volume (30 Days) | N/A | ★ 1.8M |
| Earning Date | N/A | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $18.53 |
| 52 Week High | N/A | $56.05 |
| Indicator | ACGLO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 26.65 | 80.23 |
| Support Level | $20.13 | $47.22 |
| Resistance Level | $20.34 | $56.05 |
| Average True Range (ATR) | 0.21 | 2.89 |
| MACD | -0.06 | 0.39 |
| Stochastic Oscillator | 8.57 | 85.61 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.